Lucid Diagnostics Inc.
LUCDHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeLucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company carries a $78.5M market cap, placing it firmly in the micro-cap category. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.
Market Cap
$78.5M
Beta
1.12
P/E (TTM)
—
P/E (Fwd)
-2.49
EPS (TTM)
$-0.56
EPS (Fwd)
$-0.17
ROE
-556.3%
ROA
-81.6%
Cash
$34.5M
Total Debt
$24.9M
Free CF
-$26.4M
52W Change
-67.9%
Annual Financials
Cash vs Debt
Where LUCD stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, LUCD finished 61.22% below its 150-day moving average ($0.98) and 64.15% below its 200-day moving average ($1.06). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LUCD overbought or oversold?
At the October 20, 2026 close, LUCD's RSI(14) was 11.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $34.5M in cash and $24.9M in debt, LUCD maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$26.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -556.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $500K (2021) to $4.7M (2025), reflecting a 841% increase over the period.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Lucid Diagnostics Inc. and its sector.